Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CPRX's Cash to Debt is ranked higher than
90% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. CPRX: No Debt )
CPRX' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
CPRX's Interest Coverage is ranked higher than
78% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 104.14 vs. CPRX: No Debt )
CPRX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 11.05
M-Score: -3.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -48.12
CPRX's ROE (%) is ranked higher than
52% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. CPRX: -48.12 )
CPRX' s 10-Year ROE (%) Range
Min: -1906.67   Max: -22.89
Current: -48.12

-1906.67
-22.89
ROA (%) -39.79
CPRX's ROA (%) is ranked higher than
51% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. CPRX: -39.79 )
CPRX' s 10-Year ROA (%) Range
Min: -766.07   Max: -22.19
Current: -39.79

-766.07
-22.19
ROC (Joel Greenblatt) (%) -24119.57
CPRX's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. CPRX: -24119.57 )
CPRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -108600   Max: -2321.94
Current: -24119.57

-108600
-2321.94
Revenue Growth (3Y)(%) -100.00
CPRX's Revenue Growth (3Y)(%) is ranked lower than
53% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. CPRX: -100.00 )
CPRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -100
Current: -100

EBITDA Growth (3Y)(%) 1.50
CPRX's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. CPRX: 1.50 )
CPRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 42
Current: 1.5

0
42
EPS Growth (3Y)(%) 7.10
CPRX's EPS Growth (3Y)(%) is ranked higher than
75% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. CPRX: 7.10 )
CPRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -33.7   Max: 40.8
Current: 7.1

-33.7
40.8
» CPRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CPRX Guru Trades in

Q3 2013

CPRX Guru Trades in Q3 2013

Jim Simons 138,500 sh (New)
» More
Q4 2013

CPRX Guru Trades in Q4 2013

Jim Simons Sold Out
» More
Q3 2014

CPRX Guru Trades in Q3 2014

Jim Simons 196,500 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CPRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.25
CPRX's P/B is ranked higher than
62% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. CPRX: 5.25 )
CPRX' s 10-Year P/B Range
Min: 2.33   Max: 19
Current: 5.25

2.33
19
EV-to-EBIT -11.89
CPRX's EV-to-EBIT is ranked lower than
54% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.22 vs. CPRX: -11.89 )
CPRX' s 10-Year EV-to-EBIT Range
Min: -15   Max: -1.5
Current: -11.89

-15
-1.5
Current Ratio 7.71
CPRX's Current Ratio is ranked higher than
91% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. CPRX: 7.71 )
CPRX' s 10-Year Current Ratio Range
Min: 0.75   Max: 54.56
Current: 7.71

0.75
54.56
Quick Ratio 7.71
CPRX's Quick Ratio is ranked higher than
92% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. CPRX: 7.71 )
CPRX' s 10-Year Quick Ratio Range
Min: 0.75   Max: 54.56
Current: 7.71

0.75
54.56

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.02
CPRX's Price/Net Cash is ranked higher than
95% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. CPRX: 6.02 )
CPRX' s 10-Year Price/Net Cash Range
Min: 1.36   Max: 18.63
Current: 6.02

1.36
18.63
Price/Net Current Asset Value 6.02
CPRX's Price/Net Current Asset Value is ranked higher than
91% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. CPRX: 6.02 )
CPRX' s 10-Year Price/Net Current Asset Value Range
Min: 1.36   Max: 18.63
Current: 6.02

1.36
18.63
Price/Tangible Book 5.26
CPRX's Price/Tangible Book is ranked higher than
70% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. CPRX: 5.26 )
CPRX' s 10-Year Price/Tangible Book Range
Min: 1.24   Max: 10.09
Current: 5.26

1.24
10.09
Earnings Yield (Greenblatt) -8.40
CPRX's Earnings Yield (Greenblatt) is ranked higher than
53% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. CPRX: -8.40 )
CPRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -8.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:CN2.Germany,
Catalyst Pharmaceutical Partners, Inc. was incorporated in Delaware in July 2006. The Company is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS) and infantile spasms. It has three pharmaceutical products in development namely Firdapse(tm), CPP-115 and CPP-109. In October 2012, the Company licensed the North American rights to Firdapse(tm), a proprietary form of amifampridine phosphate, or chemically known as 3,4-diaminopyridine phosphate, from BioMarin Pharmaceutical Inc. (BioMarin). CPP-115 is in the early stages of developing CPP-115, a GABA aminotransferase inhibitor that, based on its pre-clinical studies to date, it believe is a more potent form of vigabatrin, but may have fewer side effects than those associated with vigabatrin. CPP-109 was evaluated for the treatment of cocaine addiction. An academic investigator proof-of-concept study evaluating the use of CPP-109 for the treatment of Tourette syndrome is currently ongoing. The Company also competes against biotechnology companies, universities, government agencies, and other research institutions in the development of substance abuse treatments, technologies and processes. The pharmaceutical industry is intensely competitive, and any product candidate developed or licensed by the Company would likely compete with existing drugs and therapies. In the United States, drugs are subject to rigorous regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations, as well as other federal and state statutes.
» More Articles for CPRX

Headlines

Articles On GuruFocus.com
Largest Insider Buys of the Week Oct 25 2013 
Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD Jul 09 2012 
Weekly CFO Buys Highlight: EMC, DVOX, NANX, CPRX, CCRN Jun 04 2012 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Nov 15 2010 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Aug 12 2010 
Catalyst Pharmaceutical Partners Inc. (CPRX) CEO Patrick J Mcenany buys 9,359 Shares Jun 16 2010 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) May 17 2010 
Catalyst Pharmaceutical Partners Inc. (CPRX) CEO Patrick J Mcenany buys 25,000 Shares Nov 16 2009 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Nov 12 2009 
Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results Aug 07 2009 

More From Other Websites
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of... Dec 18 2014
CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 8-K, Other Events, Financial Statements and... Dec 17 2014
Catalyst Pharmaceuticals Announces the Passing of Hubert E. Huckel, Co-Founder and Director Dec 16 2014
Catalyst Pharmaceuticals Announces the Passing of Hubert E. Huckel, Co-Founder and Director Dec 16 2014
Catalyst Pharmaceuticals to Present at the Piper Jaffray 26th Annual Healthcare Conference Dec 01 2014
Catalyst Pharmaceuticals to Present at the Piper Jaffray 26th Annual Healthcare Conference Dec 01 2014
CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 8-K, Other Events, Financial Statements and... Nov 24 2014
Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction... Nov 24 2014
Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction... Nov 24 2014
CATALYST PHARMACEUTICAL PARTNERS, INC. Financials Nov 21 2014
10-Q for Catalyst Pharmaceutical Partners, Inc. Nov 15 2014
Catalyst Pharmaceuticals Announces Third Quarter 2014 Financial Results Nov 14 2014
CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 8-K, Other Events, Financial Statements and... Nov 14 2014
Catalyst Pharmaceuticals Announces Third Quarter 2014 Financial Results Nov 14 2014
CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 10-Q, Quarterly Report Nov 13 2014
Will Catalyst Pharmaceuticals' (CPRX) Loss Narrow in Q3? Nov 12 2014
Catalyst Pharmaceuticals Announces Proposed Settlement of Pending Securities Class Action Lawsuit Nov 04 2014
CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 8-K, Other Events, Financial Statements and... Nov 04 2014
Catalyst Pharmaceuticals Announces Proposed Settlement of Pending Securities Class Action Lawsuit Nov 04 2014
Catalyst Pharmaceuticals Appoints David J. Caponera as Vice President Patient Advocacy and... Oct 28 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK